Reported about 10 hours ago
WeightWatchers' stock skyrocketed 172% after announcing plans to offer compounded GLP-1 drugs as a cheaper alternative to established weight-loss medications. However, analysts warn that this approach may not be sustainable, as approval changes could hinder production once these drugs are no longer considered in short supply. Critics also claim this new strategy might undermine the company's core dieting model, with concerns over the safety and efficacy of compounded drugs further complicating its outlook.
Source: YAHOO